

Subclinical hypothyroidism in pregnancy

Abstract

It is always been controversial whether to treat subclinical hypothyroidism (SCH) or not. In last decade many clinical studies have been published about the adverse outcome with SCH in pregnant women. Due to lack of randomized prospective clinical trials, it is difficult to formulate the consensus on creating guidelines managing SCH. Here we discuss some of the data available in this regard.

Keywords: subclinical hypothyroidism, pregnancy, TSH; levothyroxine

Volume 5 Issue 6 - 2017

Lalit Mohan Bhardwaj,¹ PC Bhattacharyya²

¹DNB PGT, Department of Medicine, Downtown Hospital, India

²Senior consultant, Department of Medicine, Downtown Hospital, India

Correspondence: Lalit Mohan Bhardwaj, DNB PGT, General Medicine, Department of Medicine, Downtown Hospital, Guwahati, Assam, India, Tel +91 7896796980, Email dr.lalitmohan7@gmail.com

Received: July 29, 2017 | **Published:** August 29, 2017

Introduction

Hypothyroidism is the most common pregnancy-related thyroid disorder. Subclinical hypothyroidism is more common than is overt hypothyroidism. For patients with SCH, recommendations for therapy differ between various professional groups as a result of inconsistent data from both observational studies and clinical trials regarding the benefits for the mother or the child.

Discussion

The 20-year follow-up of the Whickham cohort¹ provided incidence data of SCH as 3.5 per 1000 women and 0.6 per 1000 men. Thyroid diseases affect up to 5% of all pregnancies. 0.3-0.5% is overt and 2.0-2.5% is SCH.^{2,3} Iodine deficiency is the most common cause worldwide for pregnancy hypothyroidism whereas chronic autoimmune thyroiditis remains most common cause in iodine sufficient region. TSH level >10mIU/l indicates overt hypothyroidism, irrespective of free T4 concentrations and usually patients have clinical symptoms.^{2,3} SCH is diagnosed when TSH is elevated but <10mIU/l and free T4 concentrations are normal.^{2,3} It is almost always asymptomatic. Fatigue and constipation are frequently observed in pregnancy and their presence does not necessarily indicate SCH.

High circulating estrogen levels in first half of pregnancy increases concentrations of thyroid binding globulin⁴ and rise in placental type II and type III deiodinases increase metabolism of T4 in the second and third trimesters. All these changes lead to an increase in the size of the thyroid gland in 15% of pregnant women, which returns to normal in the post-partum period. High prevalence of hypothyroidism in pregnancy tempted clinicians for universal screening but, rationality is still under scrutiny before recommendations for rampant use is made.

Universal screening can detect 30% of women with overt or subclinical hypothyroidism which can be missed if only high-risk women were screened.⁵ There is a huge controversy over the treatment of SCH in asymptomatic nonpregnant population. However, present data discourage indiscriminate use of thyroxine supplementation in this group. Nevertheless, same cannot be applied in the case of pregnancy as increased maternal TSH concentrations have been associated with increased risk of fetal losses,⁶⁻¹³ gestational hypertension,^{11,14-17} placental abruptions,^{15,18} preterm birth^{12,13,18-21} and poor neurological

development in the offspring.^{13,22,23} In various studies, subclinical hypothyroidism was found associated with cesarean sections,¹¹ gestational diabetes,^{18,24} breech presentation,^{25,26} infants being small for gestational age,¹² fetal distress,¹³ neonates needing intensive care treatment^{18,20} and respiratory distress syndrome.²⁰ However, some studies have found no association between adverse perinatal outcomes and hypothyroidism.²⁷⁻³²

There is a debate about whether to treat all pregnant women with subclinical hypothyroidism. Women with SCH are more likely to have TPO antibody positivity compared to euthyroid women (31% compared to 5%).³³ Up to 40% of women with positive thyroid antibodies develop hypothyroidism during or immediately after pregnancy.³⁴ Most studies evaluating the association between SCH and pregnancy outcomes was based on first trimester measures of thyroid function. Therefore, more information is needed to determine whether hypothyroidism detected in the first trimester will progress. In a study evaluating treatment for SCH, 44% of women with initially high TSH had normal thyroid function tests in a repeat sample taken 1 week later.³⁵

In non-pregnant overt hypothyroidism, full replacement doses of levothyroxine are calculated by formula 1.6µg/kg/day. In developing countries like India, clinician hardly prescribes levothyroxine in such doses. Overcorrection is not infrequent and loss of follow-up with good compliance can reverse the scenario. Keeping in mind about the potential untoward effect of SCH in pregnancy it will be prudent to treat such cases. Present data revealed that those with baseline TSH up to 4.2mIU/l required smaller levothyroxine doses (1µg/kg/day) than those with baseline TSH 4.2-10mIU/l (1.42µg/kg/day) to achieve euthyroidism.³⁶ When treating women with subclinical hypothyroidism with steady doses of levothyroxine based on their baseline TSH levels, 79, 82 and 90% of women with baseline TSH 2.5-5.0mIU/l, 5.0-8.0mIU/l and higher than 8.0mIU/l, respectively, reached euthyroidism with respective levothyroxine doses of 50, 75 and 100µg/day.³⁵ Either approach seems to be appropriate in reaching euthyroidism. The thyroxine dose should be titrated to reach a serum TSH value <2.5mIU/liter, while maintaining free T4 levels in the high normal range. Women should be followed up every 4-6 weeks with free T4 and TSH value, till delivery, to facilitate periodic adjustment of levothyroxine supplementation. Various clinical studies revealed

that different levothyroxine products might have more than 12.5% difference in levothyroxine doses.^{37,38} Many a time pharmacist changes brand without the knowledge of clinician. This may be a reason for failure to control hypothyroidism which may lead to adverse events on occasions. Levothyroxine should be ingested in the morning at least 60min before eating.³⁹ Routinely prescribed iron and calcium supplements may interfere with levothyroxine absorption, so 4 to 6hours gap can ensure adequate absorption.³⁹

There is currently insufficient evidence to show clear benefits of treating subclinical hypothyroidism.⁴⁰ In one trial randomizing women to case finding or universal screening for thyroid disease during pregnancy, 91.2% of all women with undiagnosed and untreated hypothyroidism had at least one adverse outcome, whereas the rate was 35% among those with diagnosed and treated hypothyroidism.⁴¹ However, levothyroxine treatment of SCH has been shown to reduce miscarriages in some⁴² but not all studies.⁴³ In a randomized trial, the infants of women with untreated thyroid hypofunction had similar intelligence quotient as those of women treated with levothyroxine.⁴⁴

Conclusion

Systematic review and meta-analysis of available data in this regard have sufficient evidence of poor maternal and neonatal outcomes. The effectiveness of treatment in this settings is largely unknown. The general consensus is that the universal screening, early confirmation of diagnosis and prompt treatment along with regular post-partum follow up, may ensure favorable maternal and fetal outcomes.

Acknowledgements

None.

Conflict of interest

The author declares no conflict of interest.

References

- Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. *Clin Endocrinol (Oxf)*. 1995;43(1):55–69.
- Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. *Thyroid*. 2011;21(10):1081–1125.
- De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2012;97(8):2543–2565.
- Glinoe D, de Nayer P, Bourdoux P, et al. Regulation of maternal thyroid during pregnancy. *J Clin Endocrinol Metab*. 1990;71(2):276–287.
- Vaidya B, Anthony S, Bilous M, et al. Detection of thyroid dysfunction in early pregnancy: Universal screening or targeted high-risk case finding? *J Clin Endocrinol Metab*. 2007;92(1):203–207.
- Abalovich M, Gutierrez S, Alcaraz G, et al. Overt and subclinical hypothyroidism complicating pregnancy. *Thyroid*. 2002;12(1):63–68.
- Allan WC, Haddow JE, Palomaki GE, et al. Maternal thyroid deficiency and pregnancy complications: implications for population screening. *J Med Screen*. 2000;7(3):127–130.
- Ashoor G, Maiz N, Rotas M, et al. Maternal thyroid function at 11 to 13 weeks of gestation and subsequent fetal death. *Thyroid*. 2010;20(9):989–993.
- Benhadi N, Wiersinga WM, Reitsma JB, et al. Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. *Eur J Endocrinol*. 2009;160(6):985–991.
- Negro R, Schwartz A, Gismondi R, et al. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. *J Clin Endocrinol Metab*. 2010;95(9):E44–E48.
- Sahu MT, Das V, Mittal S, et al. Overt and subclinical thyroid dysfunction among Indian pregnant women and its effect on maternal and fetal outcome. *Arch Gynecol Obstet*. 2010;281(2):215–220.
- Schneuer FJ, Nassar N, Tasevski V, et al. Association and predictive accuracy of high TSH serum levels in first trimester and adverse pregnancy outcomes. *J Clin Endocrinol Metab*. 2012;97(9):3115–3122.
- Su PY, Huang K, Hao JH, et al. Maternal thyroid function in the first twenty weeks of pregnancy and subsequent fetal and infant development: a prospective population-based cohort study in China. *J Clin Endocrinol Metab*. 2011;96(10):3234–3241.
- Ashoor G, Maiz N, Rotas M, et al. Maternal thyroid function at 11 to 13 weeks of gestation and subsequent development of preeclampsia. *Prenat Diagn*. 2010;30(11):1032–1038.
- Davis LE, Leveno KJ, Cunningham FG. Hypothyroidism complicating pregnancy. *Obstet Gynecol*. 1988;72(1):108–112.
- Leung AS, Millar LK, Koonings PP, et al. Perinatal outcome in hypothyroid pregnancies. *Obstet Gynecol*. 1993;81(3):349–353.
- Wilson KL, Casey BM, McIntire DD, et al. Subclinical thyroid disease and the incidence of hypertension in pregnancy. *Obstet Gynecol*. 2012;119(2 Pt 1):315–320.
- Casey BM, Dashe JS, Spong CY, et al. Perinatal significance of isolated maternal hypothyroxinemia identified in the first half of pregnancy. *Obstet Gynecol*. 2007;109(5):1129–1135.
- Jones WS, Man EB. Thyroid function in human pregnancy. VI. Premature deliveries and reproductive failures of pregnant women with low serum butanol-extractable iodines. Maternal serum TBG and TBPA capacities. *Am J Obstet Gynecol*. 1969;104(6):909–914.
- Casey BM, Dashe JS, Wells CE, et al. Subclinical hypothyroidism and pregnancy outcomes. *Obstet Gynecol*. 2005;105(2):239–245.
- Stagnaro-Green A, Chen X, Bogden JD, et al. The thyroid and pregnancy: a novel risk factor for very preterm delivery. *Thyroid*. 2005;15(4):351–357.
- Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med*. 1999;341(8):549–555.
- Williams F, Watson J, Ogston S, et al. Mild maternal thyroid dysfunction at delivery of infants born ≤ 34 weeks and neurodevelopmental outcome at 5.5 years. *J Clin Endocrinol Metab*. 2012;97(6):1977–1985.
- Tudela CM, Casey BM, McIntire DD, et al. Relationship of subclinical thyroid disease to the incidence of gestational diabetes. *Obstet Gynecol*. 2012;119(5):983–988.
- Kooistra L, Kuppens SM, Hasaart TH, et al. High thyrotrophin levels at end term increases the risk of breech presentation. *Clin Endocrinol (Oxf)*. 2010;73(5):661–665.
- Kuppens SM, Kooistra L, Wijnen HA, et al. Maternal thyroid function during gestation is related to breech presentation at term. *Clin Endocrinol (Oxf)*. 2010;72(6):820–824.

27. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, et al. Maternal thyroid hypofunction and pregnancy outcome. *Obstet Gynecol.* 2008;112(1):85–92.
28. Männistö T, Väärasmäki M, Pouta A, et al. Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: a prospective population-based cohort study. *J Clin Endocrinol Metab.* 2009;94(3):772–779.
29. Männistö T, Väärasmäki M, Pouta A, et al. Thyroid dysfunction and autoantibodies during pregnancy as predictive factors of pregnancy complications and maternal morbidity in later life. *J Clin Endocrinol Metab.* 2010;95(3):1084–1094.
30. Ashoor G, Maiz N, Rotas M, et al. Maternal thyroid function at 11-13 weeks of gestation and spontaneous preterm delivery. *Obstet Gynecol.* 2011;117(2 Pt 1):293–298.
31. Karagiannis G, Ashoor G, Maiz N, et al. Maternal thyroid function at eleven to thirteen weeks of gestation and subsequent delivery of small for gestational age neonates. *Thyroid.* 2011;21(10):1127–1131.
32. Williams FL, Watson J, Ogston SA, et al. Maternal and umbilical cord levels of T4, FT4, TSH, TPOAb, and TgAb in term infants and neurodevelopmental outcome at 5.5 years. *J Clin Endocrinol Metab.* 2013;98(2):829–838.
33. Jayme JJ, Ladenson PW. Subclinical thyroid dysfunction in elderly. *Trends Endocrinol Metab.* 1994;5:79–86.
34. Glinoe D, Riahi M, Grun JP, et al. Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid disorders. *J Clin Endocrinol Metab.* 1994;79(1):197–204.
35. Yu X, Chen Y, Shan Z, et al. The pattern of thyroid function of subclinical hypothyroid women with levothyroxine treatment during pregnancy. *Endocrine.* 2013;44(3):710–715.
36. Abalovich M, Vázquez A, Alcaraz G, et al. Adequate levothyroxine doses for the treatment of hypothyroidism newly diagnosed during pregnancy. *Thyroid.* 2013;23(11):1479–1483.
37. Blakesley V, Awni W, Locke C, et al. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? *Thyroid.* 2004;14(3):191–200.
38. Hennessey JV. Generic vs name brand L-thyroxine products: interchangeable or still not? *J Clin Endocrinol Metab.* 2013;98(2):511–514.
39. Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. *Best Pract Res Clin Endocrinol Metab.* 2009;23(6):781–792.
40. Vissenberg R, van den Boogaard E, van Wely M, et al. Treatment of thyroid disorders before conception and in early pregnancy: a systematic review. *Hum Reprod Update.* 2012;18(4):360–373.
41. Negro R, Schwartz A, Gismondi R, et al. Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. *J Clin Endocrinol Metab.* 2010;95(4):1699–1707.
42. Kim CH, Ahn JW, Kang SP, et al. Effect of levothyroxine treatment on in vitro fertilization and pregnancy outcome in infertile women with subclinical hypothyroidism undergoing in vitro fertilization/intracytoplasmic sperm injection. *Fertil Steril.* 2011;95(5):1650–1654.
43. Michalakis KG, Mesen TB, Brayboy LM, et al. Subclinical elevations of thyroid-stimulating hormone and assisted reproductive technology outcomes. *Fertil Steril.* 2011;95(8):2634–2637.
44. Lazarus JH, Bestwick JP, Channon S, et al. Antenatal thyroid screening and childhood cognitive function. *N Engl J Med.* 2012;366(6):493–501.